Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512353-24-01

Enrollment

Registered

2024-11-29

Start date

Unknown

Completion date

2025-12-31

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Brief summary

The primary endpoint of the study is the immune response enhanced or induced by autologous tumor lysate-loaded XP-DC in epithelial ovarian cancer patients.

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint of the study is the immune response enhanced or induced by autologous tumor lysate-loaded XP-DC in epithelial ovarian cancer patients.	—

Countries

Netherlands

Outcome results